Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that it will be making two presentations at the Biotech Showcase 2012 Conference in San Francisco Jan...

Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) ("Stellar" or the "Company") is pleased to announce that it has adopted a shareholder rights plan (the "Rights Plan") designed to encour...

Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce the completion of a major expansion of its keyhole limpet (megathura crenulata) hatchery facility in ...

PORT HUENEME, CA--(Marketwire - November 22, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to report two recent news stories on the company, by the Nat...

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have retained A.B. Korelin & Associates Inc. of Blaine, WA to assist the Company in its preparatio...

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) and Life Diagnostics, Inc. are pleased to announce they have entered into an exclusive manufacturing and supply agreement. Lif...

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have received the first purchase order from Sigma-Aldrich under terms of the marketing agreement b...

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have entered into an agreement for strategic business planning advisory services with LifeTech C...

PORT HUENEME, CA-- August 29, 2011 - Stellar Biotechnologies, Inc. "Stellar" (TSX-V:KLH) (U.S. OTC: SBOTF) is pleased to announce that the National Science Foundation (NSF) has granted Stellar a Ph...

PORT HUENEME, CA (August 3, 2011) -- Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have entered into an agreement for marketing and sales with...

Stellar Biotechnologies, Inc. “Stellar” (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that its President, Frank Oakes and Executive VP, Corporate Development & Finance, Darrell Brookstein r...

Stellar Biotechnologies, Inc. “Stellar” (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that its semi-annual CEO Letter to Shareholders has been released.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) is very pleased to announce that it has appointed David L. Hill, Ph.D. as a member of its board of directors.

Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces the completion of a pre-Investigational Device Exemption (pre-IDE) meeting with the U.S. Food and Drug Administration’s

Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) has appointed Michael R. McClurg to VP, Business Development & Marketing. His employment begins shortly, and Company Executive VP,...

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce successful completion of preclinical toxicity and immunogenicity testing of Stellar IMG KLH and Stellar Sub...

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that its U.S. subsidiary has been awarded a $99,000 grant from The National Science Foundation (NSF)

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the techn...

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) announces completion of preclinical toxicity and immunogenicity testing of Stellar KLH/SUBUNIT and St...

Stellar Biotechnologies, Inc. (the "Company" or “Stellar”) (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has closed the non-brokered private placement announced on October 25, 201...

Stellar Biotechnologies, Inc. (the "Company" or “Stellar”, TSX.V: KLH - U.S. OTC: SBOTF) is pleased to announce that its California subsidiary received news this week that it has been awarded two g...

Stellar Biotechnologies, Inc. (the "Company" or “Stellar”, TSX.V: KLH) announces a non-brokered private placement financing consisting of up to 6,000,000 units (the “Units”) at a purchase price of ...

Stellar Biotechnologies, Inc. announced today that its California subsidiary has been invited to submit a formal application for funding under the National Science Foundation’s (NSF) Technology Enh...

Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) has been advancing on several fronts over their first quarter as a public company, and expects to achieve new milestones before year end. ...

Stellar Biotechnologies, Inc. received payment of US$ 288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company

Stellar Biotechnologies, Inc. (Stellar) is pleased to announce that it has agreed to complete a CDN$ 1.05M private placement subject to acceptance by the TSX Venture Exchange

Stellar Biotechnologies, Inc. is collaborating with Bayer Innovation GmbH (BIG) in the development of biopharmaceuticals.

Stellar Biotechnologies, Inc. (PINK SHEETS: SBOTF & TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune statu...

Stellar Biotechnologies, Inc. is pleased to announce that eminent biochemist, Malcolm Gefter, Ph. D. has accepted appointment to both Stellar's Board of Directors and to its Scientific Advisory Boa...

Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) has appointed John S. Sundsmo, Ph.D., VP - Research & Intellectual Property Management and Daniel C. Adelman, M.D. as a member of the Scienti...

Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) is pleased to announce that it has released its new customer and investor-friendly website at www.StellarBiotechnologies.com.

Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) will initiate preclinical testing of its immunogenic agent, Stellar KLH/NeoA, in anticipation of filing an IND application for its Stellar KL...

Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) (“Stellar”) is pleased to announce that its long-term customer, Neovacs SA - Paris (Paris Alternext: ALNEV), recently reached significant mile...

Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed Herbert S. Chow, Ph.D., VP: Product Development.

Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed Dr. Andrew Saxon, a world-renowned expert in human cellular and molecular immunology, Chairman - SAB. Dr. Saxon is Professor & C...

Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed eminent scientist Daniel E. Morse, Ph. D. as Director and Executive VP: Science & Technology effective April 19, 2010.

CAG Capital Inc. (now Stellar Biotechnologies, Inc.) (OTC: SBOTF, TSX-V: KLH) (the “Company”) is pleased to announce the closing of the acquisition of Stellar Biotechnologies, Inc.